CLINICAL_TRIALS
trial_result
· 2022-12-07
Clinical Trial Update: Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes [Phase 4]
Summary
A Phase 4 trial investigating the role of canagliflozin on CD34+ cells in patients with type 2 diabetes; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: George Washington University | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2022-12-07